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Introduction
Endothelium remodeling is a cardinal process for the cause of mortality concerned inflammation related diseases such as Coronary Artery Disease (CAD), Myocardial infarction (MI), 1 Diabetic Retinopathy (DR), 2 Tumor, 3 Rheumatiod Arthritis (RA), 4 Primary Sclerosing Cholangitis (PSC), 5 Severe Preeclampsia (SPE), 6 Fuchs Uveitis (FU), Hashimoto Thyroiditis (HT) 7 and Microvascular Complication (MC) 8 etc. Deregulated endothelium enhances endothelial permeability to lipoproteins and other plasma components that increases the adhesive capacity with up-regulated leukocyte adhesion molecules (L-selectin, integrins, and platelet endothelial-cell adhesion molecule 1 (PECAM-1)) and endothelial adhesion molecules (including E-selectin, P-selectin, endothelial intercellular adhesion molecule-1 (ICAM-1), vascular cellular adhesion molecule (VCAM-1)). The key molecule is the ICAM-1, member of the adhesion immunolglobulin superfamily 9,10 that maps to chromosome 19 p13.2-p13.3 codes for 505 amino acids possess 5 extracellular domains including circulatory leukocytes binding site (primarily monocytes) for recruiting it at the sites of inflammation and the tight adhesion with vascular endothelium for the above mentioned pathogenesis as an initial step. Epidemiological studies are reported from various parts of the world but still the results are controversial 11,12 and inconclusive. 13, 14 Hence the objective of the current paper is to review the Genome Wide Association (GWA) studies and summarizes its understanding of functional Single Nucleotide Polymorphism (SNP's) of ICAM-1 clinical association to provide better guidance for the clinicians and researchers of the merits, demerits of the current results and direct them to perform research on larger number of population for better prospective.
Cell adhesion molecular family (CAM)
Selectin family (E, P and L-selectin), immunoglobulin super family (ICAM, PECAM-1 and VCAM-1) and integrins (CD11/18) belongs to CAM that helps the cells interactions. The rapid cycle of attachment, detachment and reattachment underlying rolling of leukocyte through the glycoprotein and glycolipids containing sialyl-Lewisx (sLex, CD 15s) structure 11 is found on neutrophils, monocytes, and some lymphocytes that interact with selectins. They are clustered in tandem within a 220-kb region of chromosome 1q23. 12 Activated endothelium 13 transiently expresses E-selectin (ELAM-1, SELE, CD62E) which supports rolling of neutrophils, monocytes, eosinophils, and some lymphocytes. There are five members 14 of ICAM immunoglobulin super family. Human ICAM-1 gene posses 7 exons and 6 introns making a total of 15.5 kb size in which protein coding region is of 3.3e3.5 kb. ICAM-1 gene structure and its up regulation process at the transcriptional and its post transcriptional have been reported more than a decade before. 15 Its regulation is governed by major pathways for the activation of sICAM-1 are NF-kB (TNF-a, IL-1b) and Janus kinases (JAK)-signal transducers signal transduction (STAT) (IFN-g) pathway through cis-elements in proximal NF-kB binding site and IFN-g responsive element (IRE) located about 200 bp and 100 bp upstream of the translational start site respectively. ICAM-1 promoter region also contain many AP-1 site in the promoter for its expression via MAP kinase pathways, (through extracellular signal-regulated kinase (ERK), the c-Jun aminoterminal kinase (JNK), and the p38 kinase) important for ICAM-1 expression in endothelial cells. The ICAM-1 variants are present in introns, exons and promoter region. It is well known that intronic variants have the potential to effect a change in mRNA (messenger Ribonucleic Acid) processing and stability that can result in aberrant splicing 16 causing altered cellecell interaction. ICAM-2 gene is located on chromosome 17 region q23-25, codes for a family of type I cell surface glycoprotein which are characterized by immunoglobulin-like extracellular Ctype domains that vary in number between two and nine (ICAMe2, -4 have two, and ICAM-1, -3 have five, ICAM-5 have nine domains) followed by a transmembrane region and a cytoplasmic domain. The cell-surface ligands are integrin lymphocyte function-associated antigen-1 LFA-1 (CD18/ CD11a, L2), and (ICAM-1, -2, and -4) integrin Mac-1 (macrophage antigen-1) (CD18/CD11b, M2) and (ICAM-3) novel integrin CD18/CD11d, D2. 17 Leukocytes, endothelial cells and platelets express ICAM-2 (CD102) constitutively but the expression remains at basal levels by inflammatory cytokines or other treatments under all conditions studies. 18 ICAM-3(CD 50) also constitutively expressed highly on the surface of almost resting leucocytes (neutrophils, monocytes, and lymphocytes whereas endothelium ICAM-3 expression is low in inflammatory diseases. It may be important in the generation of immune responses. 19 Red Blood.
Cell (RBC) specifically expresses ICAM-4 whereas ICAM-5 (telencephalin, TLN) is expressed only by neurons within the telencephalon of mammalian brains. Platelet or endothelial cell adhesion molecule-1 PECAM-1 (CD31 antigen) mapped to chromosome 17 in the region 17q23 is expressed on the surface of circulating platelets, monocytes, neutrophils, and particular T cell subsets are implicated in transendothelial migration of leukocytes, angiogenesis, and integrin activation. Mononuclear cell-specific adhesion molecule VCAM-1 (CD106) mapped to 1p32-p31 was found only on the surface of mononuclear cells and not on normal endothelium at baseline. Macrophages and dendritic cells, its counter receptor is the integrin very late antigen-4 (VLA-4, CD49d/CD29 and a4b1) is expressed on monocytes, lymphocytes, and eosinophils, but not on neutrophils. Interaction between VLA-4 and VCAM-1 plays major role in binding of this cell to activated endothelial cells.
ICAM-1
The ICAM-1 exists as membrane bound and soluble (sICAM-1) glycoprotein. Membrane bound protein belongs to type 1 transmembrane with molecular weight varies on glycosylation pattern (unglycosylated 60 KDa and glycosylated 80e114 KDa). It was demonstrated to be expressed also in leukocytes and endothelial cells (EC). This protein has extracellular portion (attached to a 24 residues single hydrophobic transmembrane region), transmembrane and a 28 residues short cytoplasmic tail. Five extracellular domains (D-1 to D-5) contain 453 amino acids, mostly hydrophobic and its b-sheet structure is stabilized by di-sulfide bond. 20 The D1 and D3
interact with their ligands LAF-1 and Mac-1 on leukocytes correspondingly and the tyrosine residue of cytoplasmic tail mediates the signaling pathway. Trans-endothelial migration of leukocytes to the site of inflammation occurs in four steps through rolling and leukocyte integrin tethering attachment (Endothelial E-and P-selectin binding), activation of integrins by chemokines (increased adhesion to ligands), firm adhesion (LFA-1, Mac-1) and leukocyte migration into sub-endothelial surface. ICAM-1 causes leukocyte transmigration by EC junctional adhesion molecules weakening and contraction via inducing intracellular Ca 2þ levels leading to the activation of p38 and Rho. 21 Like membrane bound ICAM-1, it possess extracellular domain except transmembrane and cytoplasmic region. sICAM-1 is expressed on the wide variety of human cells such as vascular EC, saphenous vein EC, aortic smooth muscle cell, astrocytes, keratinocytes and carcinoma cells. It released in to circulation through the proteolytic cleavage of extracellular region of membrane bound ICAM-1 by Matrix Metalloproteinases (MMP), human leukocyte elastase and TNF-a converting enzyme (TACE) 22 and its level may be detected in blood and other body fluids. The advantages of sICAM-1 binding with its ligands have been suggested explored to utilize it as a potential agent to block interaction of leukocyte and endothelial. 23 Recent studies suggested that circulating serum sICAM-1 concentration can be used predict the risk of post transplant ischemic events or cardiac graft failure and CAD. 
ICAM-1 and its molecular pathogenesis mechanism
The interaction between lipids, the endothelium, circulating and tissue inflammatory cells (leukocytes), platelets and vascular smooth muscle cells and extracellular matrix in the intima of large arteries results in pathogenesis of disease, are one of the earliest and critical events. In case of atherosclerosis, hyperlipidemia causes slowing down of circulating leukocytes in the streaming blood by rolling and tethering of circulating leukocytes in the monocytes and lymphocytes along the arterial endothelial lining, mediated by the selectin class of adhesion molecules and subsequent firm attachment to endothelial cells and transendothelial migration of these adherent leukocytes across the endothelial surface to the intima of the blood vessels wall. Its accumulation in the intima is mediated by b2-integrins by interacting with counter ligands from the Ig superfamily including the ICAM-1 in activated endothelial cells, where monocytes transform into lipid engorged "foam cells" by the uptake of lipids that which results of fatty streak lesions formation. The secretion of cytokines and growth factors are also important events in the initiation and progression of atherosclerotic plaques 25 as shown in Fig. 2 incontrast to normal endothelium as shown in Fig. 1 .
Discussion
ICAM-1 is a well-known identified critical molecule secreted by endothelium during vascular inflammation and is responsible for formation, growth and rupture of atheroma.
26 35 Clinical studies also suggested that ICAM-1 genotypes were not related to CAD severity, 36 intima medial thickness and coronary artery calcium.
11
Classical risk factors such DM, HTN, hyperlipidemia and smoking parameters, either alone or in combination provides invaluable information in predicting the risk of CAD due to the disease complexity. Hence, the search for biomarkers to validate risk factor was necessitated. Studies attaining this objective have shown the synergistic effect of rs5498 polymorphisms with smoking and triglycerides (G allele) posess threats to CAD 64 risk like other risk factors such DM 2 (AA genotype: K469E), HTN and low HDL concentration. 65 GWA investigation studied four novel loci and showed that ICAM-1 (K469E) polymorphism determines the circulating concentration of sICAM-1 66 apart from G241R.
Circulating levels of sICAM-1 showed positive and negative associations 30 with atherosclerosis particularly with CAD and unstable angina patients. Studies 67 were carried to determine whether polymorphism affects the sICAM-1 levels or cell cellecell binding ability. It concluded that G241R/K469E polymorphisms are responsible for expression pattern and not i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 2 8 2 e2 8 7 concerned with binding abilities. Several studies had shown that sICAM-1 may be used to predict post operative LCO event 68 in pulmonary artery hypertensive patients, MI progress and recurrence after thrombolysis. 69 It was also found to have inverse relation with left ventricular ejection fraction. 70 Clinical studies have shown that pitavastatin stimulated urocortin-1, 71 belongs to corticotrophin releasing factor/Urotensin I family to be safe and effective anti-inflammatory and may be used as a new line of atherosclerosis related diseases treatment in future. The results of genotypes are still debatable except in Chinese population than the rest of the world, as the publication's and sample size are less. Even the limited number of publication doesn't permit us for meta-analysis of data in that particular region. This might be attributable to high cost involved in genotyping techniques such Polymerase Chain Reaction-Fragment Length Polymorphism (PCR-RFLP), 30 sequencing or real time RCR 29 which are commonly employed by the researchers. Hence, we suggest the use of reliable, convenient and less time consuming novel genotyping method of Polymerase Chain Reaction with Confronting Two Pair Primer (PCR-CTPP). 72 This method involves normal PCR reaction with four primers (a pair forward and reverse primer) followed by agarose gel electrophoresis and has been demonstrated in clinical samples. 73 The designing of primers could be done using prim-SNPing online software tool. In general beyond ethnicity, ICAM-1 K469 E and G241R genotype is found to be common variant in the diseased population and may be promising molecule particularly for clinical and sub-clinical atherosclerosis. Thus, we conclude that future studies should focus on adopting reliable, cost effective and less time consuming methods to perform K469E i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 2 8 2 e2 8 7
and G241R genotyping on large number of similar ethnic groups and thereby making it possible to establish the real fate of genotype for the benefit of the society.
